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Abstract
Background: Developing vaccines for the prevention of human infection by H5N1 influenza
viruses is an urgent task. DNA vaccines are a novel alternative to conventional vaccines and should
contribute to the prophylaxis of emerging H5N1 virus. In this study, we assessed whether a single
immunization with plasmid DNA expressing H5N1 hemagglutinin (HA) could provide early
protection against lethal challenge in a mouse model.
Methods: Mice were immunized once with HA DNA at 3, 5, 7 days before a lethal challenge. The
survival rate, virus titer in the lungs and change of body weight were assayed to evaluate the
protective abilities of the vaccine. To test the humoral immune response induced by HA DNA,
serum samples were collected through the eye canthus of mice on various days after immunization
and examined for specific antibodies by ELISA and an HI assay. Splenocytes were isolated after the
immunization to determine the antigen-specific T-cell response by the ELISPOT assay.
Results: Challenge experiments revealed that a single immunization of H5N1 virus HA DNA is
effective in early protection against lethal homologous virus. Immunological analysis showed that
an antigen-specific antibody and T-cell response could be elicited in mice shortly after the
immunization. The protective abilities were correlated with the amount of injected DNA and the
length of time after vaccination.
Conclusion:  A single immunization of 100 μg H5 HA DNA vaccine combined with
electroporation was able to provide early protection in mice against homologous virus infection.
Background
The outbreak of human infections of H5N1 influenza in
1997 in Hong Kong and in 2003–2004 in most Asian
countries demonstrated that purely avian viruses could be
transmitted to humans and cause severe disease [1]. Prior
to the Hong Kong outbreak, H5 influenza viruses had
been isolated only from avian species [2]. They exist in a
non-pathogenic form in wild aquatic birds in different
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regions of the world and in domestic ducks in Southern
China [2-4]. Highly pathogenic avian influenza (HPAI)
H5N1 viruses are now enzootic in several countries and
are presently undergoing unprecedented geographic
expansion among wild and domestic birds [1,5-8]. Some
person-to-person transmissions in family clusters have
been observed in Vietnam, Thailand and Indonesia [9-
11]. Although all H5N1 viruses isolated from humans
retain characteristic features of avian influenza viruses and
are not currently transmissible among humans, the poten-
tial for a pandemic caused by H5N1-HPAIV is increasing
[8,12].
To prevent influenza, a protective immunity must be
induced, in advance, by vaccination. Immunization with
inactivated vaccines has been the main technique used to
prevent avian influenza for a long time. Some studies
demonstrated that inactivated H5 vaccines could protect
chickens and mice against the challenge with the homol-
ogous virus [7,13,14]. Meanwhile, it has been reported
that immunizations with avian influenza H5N1 inacti-
vated vaccines induced protective antibodies in humans
[5,15,16]. Immunization with DNA vaccines is also one of
the strategies for preventing avian influenza. Many studies
showed that DNA vaccines could provide protection for
chickens and mice against avian influenza types H3, H5,
H7 and H9 [7,17-22]. Our previous studies also showed
that both hemagglutinin (HA)- and neuraminidase (NA)-
DNA vaccines could protect mice from the challenge with
either influenza A or B viruses [23-28].
In this study, an avian influenza virus strain A/Chicken/
Henan/12/2004 (H5N1) was isolated from a farmed
chicken in Henan province, China. The H5 virus was
found to be able to replicate in BALB/c mice without
adaptation and caused mortality, which demonstrated the
infectivity of influenza H5N1 virus among species. The
HA gene was cloned from the virus and the abilities of an
HA DNA vaccine to provide protection for BALB/c mice
against homologous virus infection were explored. We
showed that a single immunization of H5N1 DNA vac-
cine was able to provide early protection in mice against
homologous virus infection.
Methods
Virus
The virus A/Chicken/Henan/12/2004(H5N1) was iso-
lated from a farmed chicken in Henan province, China.
Viral isolates were identified by the hemagglutination
assay after inoculating the allantoic cavity of 10 day-old
specific pathogen-free (SPF) chicken embryos. Three days
after the inoculation, allantoic fluids from infected eggs
were harvested, aliquoted and stored in at -80°C. The
50% embryo lethal dose (ELD50) was determined for each
stock and the viruses were subsequently isolated in a
Biosafety Level 3 (BSL-3) facility. The viral RNA from the
isolates propagated in 10-day-embryonated eggs was
extracted by the cleavage of viruses with Trizol LS Reagent
(Life Technologies, Inc.). The RNA was reverse-transcribed
into single-stranded cDNA with a first strand cDNA syn-
thesis kit (AMV) (Roche Diagnostics). The viral HA gene
was amplified by PCR using the Expand High Fidelity PCR
System (Roche Diagnostics) with virus-specific primers (F
Primer 5'-GGTCTCGAGTGTCAAAATGGAGAAAATAGT-
GCTT-3', XhoI site and start codon in bold; R Primer, 5'-
TCTCCCGGGACAAATTTAAAT GCAAATTCTGCAT-3',
Sma I site and stop codon in bold), then sequenced by the
dideoxy method using an ABI PRISM 377 DNA Sequencer
(Applied Biosystems).
The virus was found to be able to directly replicate in
BALB/c mice without adaptation and caused mortality
(data not shown). To prepare adapted virus to mice, lung-
to-lung passages were performed. Briefly, the BALB/c mice
were anesthetized and inoculated with 20 μl of the above-
mentioned H5N1 viral suspension by intranasal drip. At
the 3rd day after inoculation, the mice were sacrificed, and
their trachea and lungs were taken out and washed 3 times
with a total of 2 ml of phosphate buffered saline (PBS)
containing 0.1% bovine serum albumin (BSA). The bron-
choalveolar washings were collected and used for infect-
ing the next batch of mice after removing the cellular
debris by centrifugation [28]. The lung-to-lung passages
were repeated at least three times and the adapted viruses
were harvested, aliquoted, and stored in at -80°C. The
50% mouse lethal dose (MLD50) of each stock was deter-
mined using the Reed-Muench method [29].
Plasmid DNAs
The plasmid pCAGGSP7/HA (HA DNA) was constructed
by cloning the PCR product of the HA gene from A/
Chicken/Henan/12/2004 (H5N1) influenza virus strain
into the expression vector pCAGGSP7, as described previ-
ously [23,30]. The nucleotide sequence of the HA gene
was confirmed by the dideoxy method using ABI PRISM
377 DNA Sequencer (Applied Biosystems). The plasmid
was propagated in Escherichia coli XL1-blue bacteria and
purified using QIAGEN Purification Kits (QIAGEN-tip
500).
Nucleotide sequence accession numbers
The HA gene sequence from A/Chicken/Henan/12/2004
(H5N1) has been deposited in GenBank. The accession
number is AY950232.
Immunization by in vivo electroporation
For immunization, the BALB/c mice were anaesthetized
with a mixture of ketamine and lobelanine and injected
with HA DNA into the right quadriceps muscle. A pair of
5-mm-apart electrode needles (26-gauge) was thenBMC Infectious Diseases 2009, 9:17 http://www.biomedcentral.com/1471-2334/9/17
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inserted into the muscle to cover the DNA injection sites
and electrical pulses were delivered using an electric pulse
generator (Electro Square Porator T830 M; BTX, San
Diego, CA). Three pulses of 100 V each were delivered to
the injection site at a rate of one pulse per second, each
lasting for 50 ms [31]. Three pulses of the opposite polar-
ity were then applied. All procedures described above
have been reviewed and approved by Animal Care Com-
mittee of Wuhan Institute of Virology, Chinese Academy
of Sciences.
Infection
The mice were anesthetized and challenged with the
mouse-adapted strain A/Chicken/Henan/12/
2004(H5N1) (5 LD50) by intranasal administration with
20 μl of the viral suspension at 3, 5 or 7 days after immu-
nization. This infection caused rapid and widespread viral
replication in the lung and death of the control non-
immunized mice within 7–10 days [32].
Specimens
Blood samples were collected from either medial or lateral
canthus of mice on various days after immunization for
antibody detection. For lung virus titration, mice were sac-
rificed three days after the viral challenge. A ventral inci-
sion was made along the median line from the xiphoid
process to the point of the chin. The trachea and lungs
were taken out and washed twice by injecting 2 ml of PBS
containing 0.1% BSA. The bronchoalveolar wash was
used for virus titration after removing cellular debris by
centrifugation [27].
Antibody detection by ELISA and HI assay
The serum IgM and IgG Abs against HA were measured by
ELISA. ELISA was performed sequentially in a 96-well pol-
ystyrene microtiter plate with reagents consisting of: 1)
HA molecules purified from the H5N1 virus [33]; 2) serial
two-fold dilutions of sera from mice; 3) goat anti-mouse
IgG or IgM Ab (Southern Biotechnology Associates, Inc.
USA) conjugated with biotin; 4) streptavidin conjugated
with alkaline phosphatase (Southern Biotechnology Asso-
ciates, Inc. USA); and 5) p-nitrophenyl-phosphate. The
amount of chromogen produced was measured based on
absorbance at 414 and 405 nm in a Labsystems Multiskan
Ascent Autoreader (model 354, Finland). The Ab-positive
cut-off values were set as mean + 2 SD of non-immunized
sera. An ELISA Ab titer was expressed as the highest serum
dilution giving a positive reaction.
The serum neutralization activity was measured by
hemagglutination inhibition assays[34]. Receptor
destroying enzyme (RDE)-treated sera were serially
diluted (2 fold) in V-bottom 96-well plates. Approxi-
mately 4 HA units of viral antigen was incubated with the
serum for 30 min at room temperature, followed by the
addition of 0.5% cRBCs and incubation at room temper-
ature for 40 min. The inhibition of hemagglutination at
the highest serum dilution was considered as the HI titer
of the serum.
ELISPOT
Specific cellular immune responses were assessed by IFN-
γ and IL-4 ELISPOT assays using mouse splenocytes.
Assays were performed according to the instruction man-
ual (U-CyTech, Netherlands). Briefly, ELISPOT 96-well
plates Multiscreen Assay System (Millipore) were coated
with anti-mouse IFN-γ and IL-4 capture Abs and incu-
bated for 24 h at 4°C. On the following day, the plates
were washed and blocked for 2 h with 1% BSA. 2 × 105
splenocytes from the immunized mice were added to each
well and stimulated overnight at 37°C in 5% CO2 in the
presence of RPMI 1640 (negative control), Con A (posi-
tive control), or 2 μg/ml purified HA-protein [33]. After
18 h of stimulation, the cells were washed and incubated
for 1 h at 37°C with biotinylated detector antibodies (U-
CyTech). The plates were washed, and streptavidin-HRP
Conjugate (U-CyTech) was added to each well and incu-
bated for 1 h at 37°C. The plate was washed, and AEC
coloring system (U-CyTech) was added to each well. The
plates were then rinsed with distilled water and dried at
room temperature. Spots were counted by an automated
ELISPOT Bioreader 4000 (Bio-Sys Limited Germany)
[35]. The results were expressed as the number of spot
forming cells (SFC) per 106 splenocytes cells in the ELIS-
POT experiment
Virus titration
The bronchoalveolar wash was diluted 10-fold serially
starting from a dilution of 1:10, inoculated on Madin
Darby canine kidney (MDCK) cells, incubated at 37°C
and examined for cytopathic effect 2 days later. The virus
titer of each specimen, expressed as the 50% tissue culture
infection dose (TCID50), was calculated by the Reed-
Muench method [29]. The virus titer in each experimental
group is represented by the mean ± SD of the virus titer per
ml of specimens from all mice in each group.
Statistical analysis
Statistical parameters (average values and standard devia-
tions) were calculated using spss10.0 software. For com-
parisons of experimental groups, statistical analysis was
performed using one-way ANOVA.spss for windows 10.0.
p < 0.05 was considered significant. For survival, the prob-
ability was calculated by using Fisher's exact test, compar-
ing the rate of survival in mice immunized with HA DNA
to that of the control groups.BMC Infectious Diseases 2009, 9:17 http://www.biomedcentral.com/1471-2334/9/17
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Results
Immunization with one HA DNA dose provided early 
protection in BALB/c mice against lethal dosage of H5N1 
virus challenge
One hundred and sixty female BALB/c mice, at the age of
6–8 weeks, were divided into 4 groups. One group, con-
taining 16 mice, was set up as control and the mice in this
group were not immunized. The mice in the remaining
three test groups (48 mice in each) were immunized at 3,
5 and 7 days, respectively, before the lethal viral chal-
lenge. To decide the injection dosage of the HA DNA, each
test group was further divided into 3 subgroups, each con-
taining 16 mice, and immunized with 10 μg, 50 μg or 100
μg of HA DNA, respectively. As for the challenge, all the
mice, including the test and control groups, were infected
by intranasal drip with a lethal dose (5 LD50) of homolo-
gous H5N1 virus. Three days after the infection, 4 mice
from each subgroup and the control were taken out and
killed for titration of residual lung virus. The rest of mice
were observed for three weeks to evaluate the protective
ability of the HA DNA by survival rate and bodyweight
loss. The results are shown in Table 1 and Figure 1. Com-
pared with the control, the mice immunized 3 days before
the viral challenge, regardless of the injection dosage, had
no significant difference in lung virus titers compared
with the control mice. When mice were immunized 5 or 7
days before viral challenge, they had significantly lower
lung virus titers than the control after lethal infection and
the lung virus titer decreased as the injection dosage
increased. The survival rate was also related to the immu-
nization time and dosage. Mice immunized 3 days before
viral challenge with HA DNA showed the survival rate of
0%, regardless of the injection dosage. Those immunized
5 days before viral challenge with HA DNA at the dosage
of 10 μg, 50 μg and 100 μg showed the survival rate of 0%,
33% and 50%, respectively. When the mice were immu-
nized 7 days before viral challenge, the mice had the sur-
vival rate of 50%, 83% and 100%, respectively, at the
dosage of 10 μg, 50 μg and 100 μg. By contrast, the non-
immunized mice all died within 7 days after the challenge
and the lung virus titer reached as high as 106 TCID50
(Table 1). Bodyweight loss measurements also displayed
the corresponding changes. The mice that gained better
protection lost less bodyweight and therefore recuperated
more quickly (Figure 1). These results showed that mice
would gain partial protection 5 days after immunization,
with more than 50 μg of HA DNA, and that, 7 days after
the immunization, the protective ability would greatly
increase.
Antibody response induced in mice at early stage when 
immunized once with various dosages of HA DNA
Twenty female BALB/c mice, at the age of 6–8 weeks, were
divided into 4 groups, five mice each group. One group of
non-immunized mice was set up as a control. The mice in
the three test groups were immunized once with 10 μg, 50
μg and 100 μg of HA DNA, respectively. On day 3, 5, 7, 10,
14, 21, and 28 after the immunization, blood samples
were collected from either the medial or lateral canthus of
mice. Both IgM and IgG-specific antibodies were detected
by ELISA. The results are shown in Figures 2 and 3. The
results showed that immunization once with H5 virus HA
DNA induced specific IgM and IgG antibodies in mice.
The IgM antibody could be detected in all the immunized
mice on the 3rd day after the immunization, reached the
highest titer on the 10th day, and became undetectable on
the 28th day. As for the IgG antibody, mice immunized
with either 50 μg or 100 μg of HA DNA had the specific
antibody detectable by ELISA on the 5th day, while those
with 10 μg of HA DNA failed to develop detectable anti-
body until the 7th day. The IgG antibody titer increased
gradually, and was maintained at a high level until the
Table 1: Protection of mice immunized with HA DNA vaccine against lethal H5N1 virus challengea
Lung virus titerb
(log10 TCID50/ml)
Survival rate
(No. of survivors/no. tested)
Plasmid DNA Dose
(μg)
3 days 5 days 7 days 3 days 5 days 7 days
HA
DNA
10 6.25 ± 0.35 4.80 ± 0.28c 4.25 ± 0.35c 0/12 0/12 6/12
50 5.75 ± 0.35 4.55 ± 0.07c 4.00 ± 0.70c 0/12 4/12 10/12d
100 5.75 ± 0.35 4.55 ± 0.07c 3.25 ± 0.35c 0/12 6/12 12/12d
Control 6.25 ± 0.35 0/12
a Mice were immunized once with HA DNA 3, 5 and 7 days, respectively, before the challenge and at various dosages. Then all the mice were 
challenged under anesthesia with 5 LD50 of homologous A/Chicken/Henan/12/2004(H5N1) virus. Three days after the viral challenge, the mice were 
sacrificed. The trachea and lungs were taken out and washed twice by injecting 2 ml of PBS containing 0.1% BSA. The bronchoalveolar wash was 
used for virus titration after removing cellular debris by centrifugation. The survival of mice 3 weeks after the challenge was measured.
bValues represent means ± SD of 4 mice from each group.
c Significantly different from the control groups (p < 0.05) by ANOVA.
d Significantly different from the control groups (p < 0.05) by Fisher's exact test.BMC Infectious Diseases 2009, 9:17 http://www.biomedcentral.com/1471-2334/9/17
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28th day. Meanwhile, a high injection dosage of HA DNA
induced relatively high titer of both IgM and IgG antibod-
ies. The specific antibodies were further confirmed by HI
assay (Figure 4). When mice were immunized with 10 μg
of HA DNA, HI titers could not be detected until the 10th
day after immunization. When mice were immunized
with 50 μg or 100μg of HA DNA, HI titers could be
detected on the 7th day. A high injection dosage of HA
DNA also induced a relatively high HI titer.
Cell-mediated immune response induced in mice at an 
early stage when immunized once with various dosages of 
HA DNA
Forty female BALB/c mice, at the age of 6–8 weeks, were
divided into 4 groups. One group, containing 4 mice, was
set up as a control and the mice were not immunized. The
three were test groups, each containing 12 mice, were
immunized with 10 μg, 50 μg and 100 μg of HA DNA,
respectively. Splenocytes were harvested from 4 immu-
nized mice from each group at 3, 5 or 7 days after vaccina-
tion. The ELISPOT assay was used to assess the
magnitudes of HA-specific IFN-γ (Th1) and IL-4 (Th2) T-
cell responses after mice were vaccinated with HA DNA
(Figure 5). The harvested splenocytes were stimulated
Bodyweight changes after challenge Figure 1
Bodyweight changes after challenge. Mice were immu-
nized once with 10 μg (A), 50 μg (B) and 100 μg (C) of HA 
DNA 3, 5 and 7 days, respectively, before the lethal virus 
infection. Bodyweight changes were observed for 21 days 
after infection.
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IgM antibody titers in mice immunized once with various  dosages of H5N1 virus HA DNA Figure 2
IgM antibody titers in mice immunized once with 
various dosages of H5N1 virus HA DNA. Twenty 
BALB/c mice aged 6–8 weeks were divided into 4 (n = 5) 
groups. One group of non-immunized mice was set up as a 
control. The mice in the three test groups were immunized 
once with 10 μg, 50 μg and 100 μg of HA DNA, respectively. 
Blood samples were collected on day 3, 5, 7, 10, 14, 21, and 
28 after immunization and specific IgM antibodies were 
detected by ELISA. Ab-positive cut-off values were set as 
mean + 2 SD of non-immunized sera. An ELISA Ab titer was 
expressed as the highest serum dilution giving a positive 
reaction.
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with HA protein for 18 h and scored in ELISPOT assays for
IFN-γ and IL-4 producing cells. As shown in Figure 5, only
a low number of non-specific IFN-γ and IL-4 ELISPOTs
were detected in the control groups (spots ≥ 10/106 cells).
ELISPOT background counts in wells containing spleno-
cytes in the absence of mitogens or nominal antigens were
approximately the same as those in the control groups.
The numbers of positive non-specific IFN-γ and IL-4 ELIS-
POTs (concanavalin restimulated) were high, up to 2000/
106 cells (data not shown). Compared with the non-
immunized control groups, significant numbers of HA-
specific IFN-γ and IL-4 ELISPOTs were detected in all
immunized groups (p < 0.05). A limited amount of IFN-γ
and IL-4 secreting cells could be detected on the 3rd day
after immunization. On both the 5th and the 7th days the
IFN-γ secreting cells increased greatly. The group of mice
immunized with 100 μg HA DNA elicited more IFN-γ and
IL-4 secreting cells than the group of mice immunized
with 10 μg or 50 μg DNA. Moreover, mice immunized
once with HA DNA with dosages ranging from 10 μg to
100  μg raised significant amounts of IFN-γ-producing
cells, but low levels of IL-4-producing cells, in response to
the stimulation with H5 HA protein. All immunized
groups raised 8 to 12 times more HA-specific IFN-γ-pro-
ducing cells than IL-4-producing cells, suggesting a bias
towards a Th1-type response. These results demonstrated
that the HA DNA vaccine formulation had good immuno-
genicity, and induced an early cellular immune response
(Figure 5).
Discussion
To prepare for a pandemic influenza outbreak, any
human isolate of a novel subtype should be considered as
a potential hazard against humans and the feasibility of a
vaccine production should be evaluated [36,37]. To con-
trol avian influenza, plasmid DNA vaccines have been
considered as alternatives to inactivated vaccine. Many
studies have shown that H1-, H3-, H5-, H7- and H9-DNA
vaccines could protect mice and chickens against chal-
lenge with the homologous influenza virus [20-22,28,35].
In this study, BALB/c mice were immunized once by elec-
troporation with HA DNA at different dosages. Three, 5 or
7 days after the immunization, the mice were challenged
with a lethal dose (5 LD50) of H5N1 virus. The results
showed that immunization once with 50 μg or 100 μg of
HA DNA provided partial protection for mice against
homologous H5N1 virus 5 days after immunization and
that immunization once with 100 μg provided good pro-
tection against the H5N1 virus 7 days after immunization.
We demonstrated that the immunity could be established
shortly after the vaccination with a single dose of H5N1
IgG antibody titers in mice immunized once with various dos- ages of H5N1 virus HA DNA Figure 3
IgG antibody titers in mice immunized once with 
various dosages of H5N1 virus HA DNA. Twenty 
BALB/c mice aged 6–8 weeks were divided into 4 (n = 5) 
groups. One group of non-immunized mice was set up as a 
control. The mice in the three test groups were immunized 
once with 10 μg, 50 μg and 100 μg of HA DNA, respectively. 
Blood samples were collected on day 3, 5, 7, 10, 14, 21, and 
28 after immunization and specific IgG antibodies were 
detected by ELISA. Ab-positive cut-off values were set as 
mean + 2 SD of non-immunized sera. An ELISA Ab titer was 
expressed as the highest serum dilution giving a positive 
reaction.
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HI titers in mice immunized once with various dosages of  H5N1 virus HA DNA Figure 4
HI titers in mice immunized once with various dos-
ages of H5N1 virus HA DNA. Blood samples collected 
on various days were detected for specific antibodies by 
hemagglutinin inhibition (HI) assay. No HI activity was 
detectable in non-immunized mice.
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DNA vaccine and that it afforded early protection against
H5N1 virus in mice.
The breadth of the immune responses induced by the
DNA vaccine included both cell-mediated and humoral
immunities. Although most studies with HA DNA have
reported that effective antibody responses were induced
only after a booster immunization [38-40], a single dose
of a DNA vaccine had also been proved effective [41].
Tsang et al recently demonstrated that a single intramus-
cular DNA vaccination, when combined with electropora-
tion, significantly enhanced both the onset and duration
of primary antibody response and possibly the duration
of immune memory [42]. We obtained similar results in
our previous experiments with H9 virus HA DNAs
[27,28]. The present study demonstrated that a single
dose of H5 virus HA DNA could induce specific IgM and
IgG antibodies in mice (Figures 2 and 3). The IgM anti-
body, which appears prior to other kinds of antibodies
during the immune response, was detectable in mice on
the 3rd day after immunization, reached its highest value
on the 10th day and then gradually disappeared. The IgG
antibody appeared a little later. It was detectable on the
5th day and maintained a high level over a 4-week meas-
urement. It indicated that a single dose of H5 virus HA
DNA could induce a primary antibody response and that
the level of the induced IgG antibody was long-lasting.
The cellular immune response is mediated by antigen spe-
cific CD4+ and CD8+ T cells. T cells cannot recognize free
pathogens, but instead identify infected cells and exert
effector functions, including direct cytotoxic effects and
cytokine release [43,44]. It has been reported that muscle
inoculation of DNA preferentially elicits a Th1-type
response with relatively high CTL activity [45,46]. Our
results demonstrated, besides circulating anti-influenza
virus antibodies, a potent systemic cellular immune
response following a single immunization of H5N1 HA
DNA. The mice immunized once with HA DNA in dos-
ages ranging from 10 μg to 100 μg raised significant
amounts of IFN-γ-producing cells, but low levels of IL-4-
producing cells, in response to the stimulation with H5-
HA protein (Figure 5). These findings suggested that
H5N1 DNA vaccine might be a potent inducer of systemic
type 1 T cells, which were capable of mediating protection
in the respiratory tract. The H5 HA DNA vaccine might, to
some degree, induce a cytotoxic response in a naive pop-
ulation, although the cytotoxic functionality of the CD8+
T cells was not measured.
A series of human clinical trials with inactivated H5N1
vaccines demonstrated that inactivated H5N1 vaccines,
with or without adjuvant, could elicit neutralization anti-
bodies and cross-reactive neutralization antibodies to cur-
rently circulating variant H5N1 strains [47-50]. These
clinical trials also showed us some unexpected findings.
Nolan et al. recently demonstrated the better immune
response for children compared to adults when they
received two doses of inactivated, split H5N1 vaccine and
the lower seroresponse to the H5N1 vaccines in those
who had been previously vaccinated against seasonal
influenza [49,50]. These findings suggested that pre-exist-
ing antibodies to human influenza viruses might influ-
ence the immunogenicity of H5N1 vaccines. It is worthy
to know if these findings are only limited to inactivated
vaccines. Furthermore, although the H5 HA DNA vaccine
was shown in the present study to provide early protection
against lethal challenge in mice model, how it would
behave in a human body remains unknown.
HA protein-specific IFN-γ (A) and IL-4 (B) ELISPOT Figure 5
HA protein-specific IFN-  (A) and IL-4 (B) ELISPOT. 
Splenocytes harvested from mice 3, 5 or 7 days after vaccina-
tion were stimulated with HA protein for 18 h and scored in 
ELISPOT assays for IFN-γ and IL-4 producing cells. The val-
ues represent the averages of triplicate wells of 4 mice, and 
are expressed as means ± SD. The results were expressed as 
the number of SFC per 106 input cells. * Significant difference 
(p < 0.05).BMC Infectious Diseases 2009, 9:17 http://www.biomedcentral.com/1471-2334/9/17
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Conclusion
We have demonstrated that a single immunization of 100
μg of an H5 HA DNA vaccine, combined with electropo-
ration, elicited both humoral and cellular immune
responses, which provide mice the early protection
against avian influenza H5N1 virus. It might be helpful
for the ideal of providing rapid onset of protection against
AIV infection with a "single shot" vaccine.
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